BioCryst Pharmaceuticals, Inc.
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
Asset Breakdown FY2022
Total Assets: $550.0M
Liabilities Breakdown FY2022
Total Liabilities: $844.6M
Asset Breakdown
Total Assets: $550.0M
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $304.8M | 55.4% |
| Accounts Receivable | $50.6M | 9.2% |
| Inventory | $27.5M | 5.0% |
| Property, Plant & Equipment | $8.6M | 1.6% |
| Goodwill | $0 | 0.0% |
| Intangible Assets | $0 | 0.0% |
| Other Assets | $158.5M | 28.8% |
Liabilities Breakdown
Total Liabilities: $844.6M
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $14.4M | 1.7% |
| Long-Term Debt | $231.6M | 27.4% |
| Other Liabilities | $598.6M | 70.9% |